141 related articles for article (PubMed ID: 33236570)
1. Characteristics Associated with Upper-Range Doses of Beta-Blockers and Angiotensin-Renin Inhibitors in Reduced Ejection Fraction.
Itzhaki Ben Zadok O; Murninkas D; Iakobishvili Z; Jino H; Yohananov E; Birkenfeld S; Hasdai D
Isr Med Assoc J; 2020 Jul; 22(7):441-445. PubMed ID: 33236570
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA
Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116
[TBL] [Abstract][Full Text] [Related]
3. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
[TBL] [Abstract][Full Text] [Related]
4. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
5. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
[TBL] [Abstract][Full Text] [Related]
6. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Assistance Clinic.
Bhat S; Kansal M; Kondos GT; Groo V
Ann Pharmacother; 2018 Aug; 52(8):724-732. PubMed ID: 29463107
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.
Diamant MJ; Virani SA; MacKenzie WJ; Ignaszewski A; Toma M; Hawkins NM
ESC Heart Fail; 2019 Aug; 6(4):774-783. PubMed ID: 31218850
[TBL] [Abstract][Full Text] [Related]
10. Differences in medical treatment and clinical characteristics between men and women with heart failure - a single-centre multivariable analysis.
Norberg H; Pranic V; Bergdahl E; Lindmark K
Eur J Clin Pharmacol; 2020 Apr; 76(4):539-546. PubMed ID: 31897534
[TBL] [Abstract][Full Text] [Related]
11. Heart failure medication dosage and survival in women and men seen at outpatient clinics.
Bots SH; Onland-Moret NC; Tulevski II; van der Harst P; Cramer MJM; Asselbergs FW; Somsen GA; den Ruijter HM
Heart; 2021 Nov; 107(21):1748-1755. PubMed ID: 34261736
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
[TBL] [Abstract][Full Text] [Related]
13. The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice.
Chin KL; Skiba M; Tonkin A; Reid CM; Liew D; Krum H; Hopper I
Heart Fail Rev; 2016 Nov; 21(6):675-697. PubMed ID: 27465132
[TBL] [Abstract][Full Text] [Related]
14. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
Ouwerkerk W; Voors AA; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Ter Maaten JM; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Metra M; Zwinderman AH
Eur Heart J; 2017 Jun; 38(24):1883-1890. PubMed ID: 28329163
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF.
Linssen GCM; Veenis JF; Kleberger A; Grosfeld MJW; Viergever EP; van Dalen BM; de Valk-Bedijn W; Langerveld J; Brunner-La Rocca HP; Hoes AW; Brugts JJ;
Clin Res Cardiol; 2020 Sep; 109(9):1155-1164. PubMed ID: 32030498
[TBL] [Abstract][Full Text] [Related]
17. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
[TBL] [Abstract][Full Text] [Related]
18. Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry.
Yoshikawa Y; Tamaki Y; Morimoto T; Yaku H; Yamamoto E; Inuzuka Y; Ozasa N; Kitai T; Nagao K; Sato Y; Kondo H; Tamura T; Nakagawa Y; Kuwahara K; Kato T; Kimura T
PLoS One; 2020; 15(9):e0239100. PubMed ID: 32925953
[TBL] [Abstract][Full Text] [Related]
19. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
[TBL] [Abstract][Full Text] [Related]
20. Nurse-Led Titration of Angiotensin-Converting Enzyme Inhibitors, β-Adrenergic Blocking Agents, and Angiotensin Receptor Blockers in Patients With Heart Failure With Reduced Ejection Fraction.
Driscoll A; Currey J; Tonkin AM
JAMA Cardiol; 2016 Oct; 1(7):842-843. PubMed ID: 27556747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
